Low dose mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from north India

Vidushi Kulshrestha, Alka Kriplani, Nutan Agarwal, Neetu Sareen, Pradeep Garg, Smriti Hari, Jyoti Thulkar, Vidushi Kulshrestha, Alka Kriplani, Nutan Agarwal, Neetu Sareen, Pradeep Garg, Smriti Hari, Jyoti Thulkar

Abstract

Background & objectives: Uterine myoma is a common indication for hysterectomy in India. An effective medical treatment option may reduce hysterectomy associated morbidity. This study was undertaken to evaluate efficacy and safety of low dose mifepristone in medical management of myoma and to compare two doses - 10 vs. 25 mg/day.

Methods: In this randomized clinical trial, women with symptomatic myoma or myoma>5 cm were included. Uterine size >20 wk, fibroids >15 cm were excluded. Pictorial blood loss assessment chart (PBAC) score was used to assess menstrual-blood-loss and visual analog scale (VAS) for other symptoms. Haemogram, liver function test, ultrasound with doppler and endometrial histology was performed. Patients were randomized and were given oral mifepristone as 25 mg/day in group 1 and 10 mg/day in group 2 for 3 months. Patients were followed at 1, 3 and 6 months.

Results: Seventy patients in group 1 and 73 in group 2 completed treatment. Mean PBAC score reduced from 253 to 19.8 and from 289.2 to 10.4 at 1 and 3 months in groups 1 and 2, respectively. At 3 months, 67 of 70 (95.7%) patients of group 1 and 66 of 73 (90.4%) of group 2 developed amenorrhoea which reverted after median 34 (range 4-85) days. Mean myoma volume decreased by 35.7 per cent (from 176.8 to 113.7 cm 3 ) and 22.5 per cent (from 147.6 to 114.4 cm 3 ) at 3 months in groups 1 and 2, respectively. Side effects seen were leg cramps in 7 of 70 (10%) and 5 of 73 (6.8%) and hot-flushes in 5 of 70 (7.1%) and 5 of 73 (6.8%) in groups 1 and 2, respectively. Repeat endometrial-histopathology did not reveal any complex hyperplasia or atypia in either group.

Interpretation & conclusions: Mifepristone (10 and 25 mg) caused symptomatic relief with more than 90 per cent reduction in menstrual blood. Greater myoma size reduction occured with 25 mg dose. Amenorrhoea was developed in 90-95 per cent patients which was reversible. It can be a reasonable choice for management of uterine leiomyoma as it is administered orally, cost-effective and has mild side effects.

Conflict of interest statement

Conflict of interests: Last author (JT) is presently working as Assistant Editor of IJMR. Other authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Flowchart showing the study design.
Fig. 2
Fig. 2
Effect of mifepristone (25 and 10 mg) on PBAC score.

References

    1. Adamson GD. Treatment of uterine fibroids current findings with gonadotrophin releasing hormone agonists. Am J Obstet Gynecol. 1992;166:746–51.
    1. Carlson KJ, Nichols DH, Schiff I. Indications of hysterectomy. N Engl J Med. 1993;328:856–60.
    1. Delco V la Marca A, Margante G. Short term treatment of uterine fibromyomas with danazol gynecol. Obstet Invest. 1999;47:258–62.
    1. Stovall TG, Summit RL, Jr, Washburn SA, Ling FW. Gonadotropin releasing hormone agonist use before hysterectomy. Am J Obstet Gynecol. 1994;170:1744–51.
    1. Lethaby A, Vollenhoven B, Sowter M. Preoperative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001:CD000547.
    1. Letterie GS, Coddington CC, Winkel CA, Shawker TH, Loriaux DL, Collins RL. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up. Fertil Steril. 1989;51:951–6.
    1. Pron G, Cohen M, Soucie J, Garvin G, Vanderburgh L, Bell S. The Ontario Uterine Fibroid Embolization Trial. Part 1. Baseline patient characteristics, fibroid burden, and impact on life. Fertil Steril. 2003;79:112–9.
    1. Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010;151:2433–42.
    1. Yoshida S, Ohara N, Xu Q, Chen W, Wang J, Nakabayashi K, et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med. 2010;28:260–73.
    1. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409–20.
    1. Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol. 2009;21:318–24.
    1. Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009;24:1870–9.
    1. Narvekar N, Critchley HO, Cheng L, Baird DT. Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. Hum Reprod. 2006;21:2312–8.
    1. Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception. 2010;82:442–52.
    1. Murphy AA, Morales AJ, Kettel LM, Yen SSC. Regression of uterine leiomyomata to the antiprogesterone RU 486 dose response effect. Fertil Steril. 1995;64:187–90.
    1. Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;97:734–9.
    1. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SSC. Regression of uterine leiomyomata in response to antiprogesterone RU 486. J Clin Endocrinol Metab. 1993;76:513–7.
    1. Reinsch RC, Murphy AA, Morales AJ, Yen SSC. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus. A prospective randomized study. Am J Obstet Gynecol. 1994;170:1623–8.
    1. Yang Y, Zhang S, Li K. Treatment of uterine leiomyoma by two different doses of mifepristone. Zhonghua Fu Chan Ke Za Zhi. 1996;31:624–6.
    1. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101:243–50.
    1. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. Minim Invasive Gynecol. 2005;12:227–33.
    1. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol. 2006;108:1381–7.
    1. Carbonell Esteve JL, Acosta R, Heredia B, Pérez Y, Castañeda MC, Hernández AV. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2008;112:1029–36.
    1. Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol. 2009;49:77–83.
    1. Esteve JL, Acosta R, Pérez Y, Campos R, Hernández AV, Texidó CS. Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur J Obstet Gynecol Reprod Biol. 2012;161:202–8.
    1. Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol. 2009;146:215–8.
    1. Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod. 2003;18:61–8.
    1. Heikinheimo O, Ranta S, Grunberg S, Lähteenmäki P, Spitz IM. Alterations in the pituitary-thyroid and pituitary-adrenal axes--consequences of long-term mifepristone treatment. Metabolism. 1997;46:292–6.
    1. Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol. 2004;103:1331–6.
    1. Chwalisz K, Brenner RM, Fuhrmann UU, Hess-Stumpp H, Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids. 2000;65:741–51.
    1. Fiscella J, Bonfiglio T, Winters P, Eisinger SH, Fiscella K. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum Pathol. 2011;42:947–53.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren